We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

No cure-all

6 Jan 2006 By Robert Cyran

The industry may have bright prospects, but biotech stocks have not been a cureall. Returns have been unevenly distributed and volatile. The market doesn t appear as attractive now as it did in 2002. But some value probably resides in the biotech minnows.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)